Premium
Intranasal Verapamil in Allergen‐Induced Rhinitis
Author(s) -
SECHER GLAUS,
BROFELDT SUSANNE,
MYGIND NIELS
Publication year - 1983
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.1983.tb04141.x
Subject(s) - verapamil , medicine , nasal administration , placebo , antagonist , allergen , nasal spray , pharmacology , anesthesia , allergy , calcium , immunology , receptor , alternative medicine , pathology
Twenty‐six pollen‐allergic subjects participated in a double‐blind, placebo‐controlled trial of the protective effect of the calcium antagonist, verapamil, on allergen‐provoked nasal symptoms. Intranasal verapamil, 1 mg, had a weak protective effect in that “tickling score” was 22% lower ( P < 0.01) and the number of sneezes 29% lower (nonsignificant) after verapamil as compared with placebo pretreatment. There were no differences with regard to nasal blockage or discharge. It is concluded tha the verapamil spray used, cannot be recommended for clinical trials, but that further investigations of other formulations of calcium antagonists are justified in order to analyse the potential role of this type of drugs in the treatment of allergic rhinitis.